Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutationsFilip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Oncotarget|December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomesFilip Janku, Jennifer J Wheler, Aung Naing, et al.
JCO Precision Oncology|May 9, 2024
Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic TargetsErik B Faber, Harris B Krause, Khalid Amin, et al.
Cancer Biology & Therapy|July 20, 2011
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft modelsGeorg Feldmann, Anjali Mishra, Savita Bisht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2011
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancerIgnacio Garrido-Laguna, Maria Uson, N V Rajeshkumar, et al.
The Oncologist|August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation BurdenWinnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
The Oncologist|June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid TumorsHui K Gan, Michael Millward, Mathilde Jalving, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Journal for Immunotherapy of Cancer|November 29, 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumorsTodd M Bauer, Armando Santoro, Chia-Chi Lin, et al.
Pageof 11